Lehrstuhl für Innere Medizin III

Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks (2020) Schett G, Van Den Bosch F, Baraliakos X, Sandoval D, Geneus V, Bolce R, Liu-Leage S, et al. Conference contribution A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate (2020) Peterfy C, Buch M, Choy E, Schett G, Parsons-Rich D, Patel A, Zima Y, et al. Conference contribution Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial (2020) Schett G, Loza MJ, Palanichamy A, Fitzgerald O, Ritchlin C, Baribaud F, Sweet K Conference contribution Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection (2020) Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss M, Heppt F, Meder C, et al. Conference contribution High Impact Sports Leads to Inflammatory Responses at Entheseal Sites Results of the BEAT Study (Badminton Enthesitis Arthrosonography Study) (2020) Simon D, Kleyer A, Tascilar K, Bayat S, Knitza J, Valor-Mendez L, Schweiger M, et al. Conference contribution Understanding Ankylosing Spondylitis - (2020) Kleyer A, Pachowsky M, Schuster L, Valor-Mendez L, Schett G, Hueber A, Simon D Conference contribution Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function (2020) Liphardt AM, Manger E, Liehr S, Bieniek L, Kleyer A, Simon D, Tascilar K, et al. Conference contribution Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis (2020) Kampylafka E, Tascilar K, Lerchen V, Linz C, Sokolova M, Zekovic A, Kleyer A, et al. Conference contribution Cinematic Rendering Enables Depiction of Bone Anabolic Effects in Patients Treated with Baricitinib (2020) Bayat S, Simon D, Schuster L, Schett G, Kleyer A Conference contribution NR4A1 AGONIST CYTOSPORONE B DOES NOT ATTENUATE CAV IN A MOUSE MODEL DESPITE REPORTED ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY EFFECTS (2020) Kuckhahn A, Ramsperger-Gleixner M, Distler J, Weyand M, Heim C Conference contribution